Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1989-9-27
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0305-7372
pubmed:author
pubmed:issnType
Print
pubmed:volume
16 Suppl A
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
59-63
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed-meshheading:2788507-Adult, pubmed-meshheading:2788507-Aged, pubmed-meshheading:2788507-Aged, 80 and over, pubmed-meshheading:2788507-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:2788507-Dacarbazine, pubmed-meshheading:2788507-Drug Administration Schedule, pubmed-meshheading:2788507-Drug Evaluation, pubmed-meshheading:2788507-Drug Synergism, pubmed-meshheading:2788507-Female, pubmed-meshheading:2788507-Humans, pubmed-meshheading:2788507-Interleukin-2, pubmed-meshheading:2788507-Liver Neoplasms, pubmed-meshheading:2788507-Lung Neoplasms, pubmed-meshheading:2788507-Lymphatic Metastasis, pubmed-meshheading:2788507-Male, pubmed-meshheading:2788507-Melanoma, pubmed-meshheading:2788507-Middle Aged, pubmed-meshheading:2788507-Monitoring, Physiologic, pubmed-meshheading:2788507-Recombinant Proteins, pubmed-meshheading:2788507-Remission Induction
pubmed:year
1989
pubmed:articleTitle
Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study.
pubmed:affiliation
Rotterdam Cancer Institute, The Netherlands.
pubmed:publicationType
Journal Article